Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II‐IIIA non‐small cell lung cancer: Propensity score‐matched and instrumental variable analyses

Adjuvant chemotherapy with vinorelbine plus cisplatin (VNR/CDDP) is a standard regimen for treatment of postoperative stage II‐IIIA non‐small cell lung cancer (NSCLC). However, oral fluorouracil offers a feasible alternative adjuvant chemotherapeutic regimen. We compared the prognoses of patients with NSCLC treated with adjuvant chemotherapy with either VNR/CDDP or oral fluorouracil.

[1]  W. Mackillop,et al.  The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis , 2016, Breast Cancer Research and Treatment.

[2]  Kenji Suzuki,et al.  Safety and compliance data of the phase III study of adjuvant chemotherapy for patients (pts) with completely resected, pathological (p-) stage I (T1 > 2 cm) non-small cell lung cancer (NSCLC): A Japan Clinical Oncology Group Trial, JCOG0707. , 2016 .

[3]  M. Galsky,et al.  Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Baiocchi,et al.  Instrumental variable methods for causal inference , 2014, Statistics in medicine.

[5]  Y. Imanaka,et al.  Survival analyses of postoperative lung cancer patients: an investigation using Japanese administrative data , 2014, SpringerPlus.

[6]  T. Nagayasu,et al.  A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates. , 2012, Clinical lung cancer.

[7]  E. Miyaoka,et al.  Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  W. Mackillop,et al.  Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. , 2011, JAMA.

[9]  J. Pignon,et al.  Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[12]  L. Wilson,et al.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[14]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[15]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[16]  J. Angrist,et al.  Identification and Estimation of Local Average Treatment Effects , 1994 .

[17]  J. Stock,et al.  Instrumental Variables Regression with Weak Instruments , 1994 .

[18]  H. Horiguchi,et al.  Clinical Epidemiology and Health Services Research using the Diagnosis Procedure Combination Database in Japan , 2015 .

[19]  Takaaki Sasaki,et al.  Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer. , 2013, Molecular and clinical oncology.

[20]  E. Miyaoka,et al.  Analysis of Lung Cancer Registry Cases Resected in 2004 Japanese Joint Committee for Lung Cancer Registration , 2011 .

[21]  N. Hanna.  Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database , 2007 .